Advanced searches left 3/3

Aspergillosis - Europe PMC

Summarized by Plex Scholar
Last Updated: 06 June 2022

* If you want to update the article please login/register

Aroma profile and in-silico molecular docking studies of essential oil against “Aspergillosis” from Eucalyptus polybrachtea

"Essential oil from Eucalyptus plant is used as a traditional and complementary medicine around the world. " Purpose, phosphate synthase and UDP-glycosyltransferase and UDP-glycosyltransferase constituent oil component of Eucalyptus essential oil component eucalyptol against Glucosamine-6-phosphate synthase and molecular docking as an appropriate site for developing drug against u201d and in vitro validation. Ligand Protein 2D and 3D Interactions were also investigated. Drug likeliness, safety profile, and cancer cell line toxicity were also investigated. Hydrophobic and hydrogen interactions revealed that eucalyptol forms tight complexes with Glucosamine-6-phosphate synthase, chitin synthase, and UDP-glycosyltransferase enzymes by hydrophobic and hydrogen interactions, according to Molecular docking findings. Due to a high degree of bioactivity, drug likelines, and cancer cell line toxicity, Eucalyptol also showed drug likeliness by LIPINSKY's censorship, adequate amount of bioactivity, pharmaceutical likeliness, and cancer cell line toxicity, with satisfactory clinical consistency, traceability, drug likeliness, and cancer cell line toxicity. Eucalyptus oil was able to stop the proliferation of fungal strains toxicity, thus establishing its role as a potent anti-fungal drug. ".

Source link: https://europepmc.org/article/MED/IND607700703


Cytokine response as a biomarker for early diagnosis and outcome prediction of stem cell transplant recipients and acute leukemia patients with invasive aspergillosis.

"We wanted to know the role of serum cytokine expression in invasive aspergillosis diagnosis and outcome prediction in hematologic patients," says the author. In this multicenter study, serum cytokines were prospectively recruited from all consecutive patients with hematological malignances at IA diagnosis and compared to control patients matched by location, age, baseline disease, and therapeutic regimen. Even in patients with IA who were neutropenic, serum levels of IL6 and IL10 cytokines were dramatically higher on day 0 on day 0 when compared to controls. IL6 levels at IA diagnosis are related to poor outcomes.

Source link: https://europepmc.org/article/MED/35652817


Risk factors and clinical impact of COVID-19-associated pulmonary aspergillosis: Multicenter retrospective cohort study.

"This research sought to investigate the epidemiology and value of CAPA diagnostic efforts as well as the potential predictors of CAPA and its effects on clinical outcomes. " Methods Between January 2020 and May 2021, records of critically injured COVID-19 patients were extracted from seven hospitals of the Catholic Medical Center's Catholic Medical Center in a clinical data warehouse. Corticosteroid use was divided into total cumulative dose, early 7-day dose, mean daily dose, and duration of use. In 4. 6 percent of all hospitalized and 11. 2% of emergency care unit patients, CAPA was diagnosed in 4. 6 percent of all hospitalized and 11. 2% of intensive care unit patients. Both total dose and daily high-dose corticosteroid use were estimates, but not early 7-day high-dose corticosteroid use nor long use were common. The predictor of CAPA and its high mortality rates was daily high-dose corticosteroid use. For those high-risk patients, high-dose corticosteroids use after the early inflammatory phase should be avoided, and proactive monitoring methods for CAPA are essential for those high-risk patients.

Source link: https://europepmc.org/article/MED/35611611


Association Between Early Diagnosis of and Inpatient Mortality from Invasive Pulmonary Aspergillosis Among Patients Without Immunocompromised Host Factors: A Nationwide Observational Study.

"Objectives" has been extensively discussed. "Objectives" has been used to describe the occurrence of invasive pulmonary aspergillosis among patients without immunocompromised host factors. To date, no research has definitively established the benefit of early IPA therapy in patients without ICHF. Methods We conducted a cross-sectional study on mortality from IPA among patients without ICHF using the Japanese Diagnosis Procedure Combination National Inpatient Database. The early diagnosis group had a lower mortality rate than the delayed diagnosis group. "Economists who received voriconazole were linked to reduced risk of death in the early diagnosis group.

Source link: https://europepmc.org/article/MED/35643307


Autopsy study of fatal invasive pulmonary aspergillosis: Often undiagnosed premortem.

"Invasive aspergillosis is a common complication among immunocompromised and critically ill patients, but it is difficult to diagnose. " We wanted to see how often patients go undiagnosed and what the presenting clinical and radiologic signs associated with lethal IA. We looked at cases of fatal IA confirmed at autopsy between 1999 and 2019 at a tertiary academic hospital. In 97% of cases--46% were restricted to the lungs, and 51% had concomitant extrapulmonary involvement. Chronic lung disease was present in 70% of those not immunocompromised, and a respiratory coinfection was found in 50%. In 61% of cases, diagnostic bronchoscopy was performed, but aspergillus was discovered in 63% of those cases by either bronchoalveolar lavage, bronchial washings, or transbronchial biopsy cultures. In only 27% of fatal IA cases identified at autopsy, physicians correctly identified IA as the cause of death in only 27% of the fatal IA cases recognized at autopsy.

Source link: https://europepmc.org/article/MED/35633606


Monoclonal Antibodies and Invasive Aspergillosis: Diagnostic and Therapeutic Perspectives.

"Invasive aspergillosis is a life-threatening fungal disease that causes increased morbidity and mortality in immunosuppressed patients. " Moreover, many high-risk patients receive either an empirical therapy or a continued therapy of high-priced antifungal drugs, often ending in unnecessary adverse effects and a high risk of drug resistance. Monoclonal antibodies with high specificity in compared to the corresponding antigen may have the ability to analyze diagnostic procedures and provide the basis for novel IA drugs. ".

Source link: https://europepmc.org/article/MED/35628374


Voriconazole therapeutic drug monitoring among lung transplant recipients receiving targeted therapy for invasive aspergillosis.

"Background Voriconazole is the first line drug for invasive aspergillosis in invasive aspergillosis" According to current reports, regular voriconazole therapeutic drug testing should be conducted to maximize treatment success. " In LTRs, we wanted to see if TDM was predictive of clinical outcome. Methods Retrospective chart review was conducted for all LTRs with probable or confirmed IA, who were treated with voriconazole monotherapy, and those who underwent TDM during therapy. IA-related TDM samples from 30 LTRs with IA were analyzed, yielding one hundred and eighteen TDM samples. Patients with median TDM higher than 0. 72 percent u03bcg/ml had a positive result, compared to 42. 9% of patients with a median TDM below 0. 72 percent –u03bcg/ml. Conclusions Our results show that a voriconazole TDM range of 0. 72 bcg/ml and 2. 13 bcg/ml could be related to improved outcomes. Our research is in accordance with recent studies that have been published on the use of voriconazole TDM in improving outcomes and minimizing toxicities in LTR with IA.

Source link: https://europepmc.org/article/MED/35575963


T-cell epitope-based vaccine prediction against Aspergillus fumigatus: a harmful causative agent of aspergillosis.

Aspergillus fumigatus is one of the most common causes of invasive aspergillosis and acute bronchopulmonary aspergillosis. Aspergillosis in allogeneic haematopoietic stem cell transplant recipients, HIV patients, and cancer patients is common in asthma patients. A. fumigatus is an allergy to Asthmatics and cystic fibrosis patients. Immunogenic responses in patients can be triggered by MHC class-III binding epitopes. A atomic contact energy value for these five epitopes is determined below -5 Kcal/mol in docked state, according to a Molecular docking study. Conclusions The invasive aspergillosis and acute bronchopulmonary aspergillosis are caused by the inflammatory fungal pathogen Aspergillus fumigatus. ".

Source link: https://europepmc.org/article/MED/35575941


Comparison of a novel lateral-flow device to galactomannan assay at different time periods for detections of invasive aspergillosis.

"Methods First, 20 GM-positive serum samples stored for two years were retested using both the GM and LFD assays. The second, 153 serum samples from 91 immunocompromised patients suspected of having IA were tested prospectively, including 56 hematologic malignancies and 35 chronic illnesses with steroid therapy. The LDF's concordance with the GM test was 79%, with the rate decreasing to 67 percent if the LFD test was performed 2-7 days after the GM test. The LFD assay had 89. 65% and 98. 6 percent, 66. 6 percent, and 78. 67 percent. If the tests were performed on the same day, there was a strong correlation between the LFD and GM assay results, but if the samples were stored for longer than 2 days, this decreased.

Source link: https://europepmc.org/article/MED/35570052


Clinical and Imaging Features of COVID-19-Associated Pulmonary Aspergillosis.

"The aim of this research is to compare medical and imaging findings between COVID-19 patients with and without associated pulmonary aspergillosis. " Patients with pulmonary aspergillosis are compared with 40 chest CTs of 13 CAPA patients by two observers independently compared 105 chest CTs of 52 COVID-19 patients without pulmonary aspergillosis to 40 chest CTs of 13 CAPA patients. The following characteristics were evaluated: lung involvement, the most common main pattern, and additional lung and chest measurements. Compared to COVID-19 patients without respiratory impairments, CAPA patients with respiratory aspergillosis, were younger mean age : 70. 3 versus 63. 5 years. Consolidation and ground glass evolved in tandem with time. Consolidation was associated with CAPA in early COVID-19 disease, but ground glass was less common. Regardless of the time, bronchial wall thickening was observed more often in CAPA patients. Conclusions: Early CAPA patients had a tendency toward consolidation in early COVID-19 disease.

Source link: https://europepmc.org/article/MED/35626356

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions